89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference
January 04 2021 - 8:00AM
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of liver and
cardio-metabolic diseases, today announced that Rohan Palekar, the
company’s Chief Executive Officer, will provide a corporate
update at the virtual H.C. Wainwright BioConnect 2021 Conference to
be held January 11-14, 2021.
The presentation will be available on-demand through the H.C.
Wainwright conference portal, starting at 6 a.m. EST on Monday,
January 11, 2021. An archived webcast will also be accessible in
the investor section of 89bio’s website.
About 89bio 89bio is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
liver and cardio-metabolic diseases. The company’s lead product
candidate, BIO89-100, is a specifically engineered glycoPEGylated
analog of FGF21. BIO89-100 is being developed for the treatment of
nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia
(SHTG). 89bio is headquartered in San Francisco with operations in
Herzliya, Israel.
Investor Contact: Ryan Martins Chief Financial Officer
investors@89bio.com
Media Contact: Peter Duckler 773-343-3069
pduckler@w2ogroup.com
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Mar 2024 to Apr 2024
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Apr 2023 to Apr 2024